SolasCure demonstrates proof-of-concept in Phase lla safety trial of Aurase Wound Gel Post author: Post published:December 12, 2023 Post category:uncategorized SolasCure today announced the results of its proof-of-concept, first-in-human, Phase IIa safety study. You Might Also Like Anti-HIV drugs can be used to prevent inflammatory complications of bacterial sepsis January 18, 2024 Space conditions disrupt rhythmic function of bioengineered heart tissues September 23, 2024 Risk-reducing surgeries provide benefits for young BRCA-mutation carriers December 11, 2024
Anti-HIV drugs can be used to prevent inflammatory complications of bacterial sepsis January 18, 2024